Abramson N S, Kelsey S F, Safar P, Sutton-Tyrrell K
Department of Anesthesiology, University of Pittsburgh School of Medicine, Pennsylvania.
Ann Emerg Med. 1992 Dec;21(12):1480-2. doi: 10.1016/s0196-0644(05)80066-6.
Expensive clinical trials have become the gold standard for evaluating the efficacy of promising new therapeutic agents. Full exploration of the collected data is routine to maximize the yield of the information available. However, potential methodologic flaws in these extensive analyses may not be appreciated by investigators or readers. One such problem with subgroup analyses is discussed, using hypothetical examples and data from a recently completed clinical trial of brain resuscitation as illustrations.
昂贵的临床试验已成为评估有前景的新型治疗药物疗效的金标准。对收集到的数据进行全面探究已成为常规操作，以最大限度地获取可用信息。然而，研究人员或读者可能并未意识到这些广泛分析中潜在的方法学缺陷。本文将以假设示例和最近完成的一项脑复苏临床试验数据为例，讨论亚组分析中存在的一个此类问题。
